Proliferative activity of any tissue or neoplasm can be determined by its growth rate by mitotic count or by using antibodies directed against specific antigens like Ki-67. The usefulness of Ki-67 in head and neck cancers has been debated for the past 20 years; however, no study has definitively resolved this controversy.
No takes yet. Share an insight, caveat, or question.
Deepa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: